Visual outcomes after bevacizumab-based therapy for optic pathway glioma

被引：5
|
作者：
Siegel, Benjamin I. [1 ,4 ]
Nelson, Daniel [2 ]
Peragallo, Jason H. [2 ]
Macdonald, Tobey J. [1 ]
Wolf, David S. [1 ,3 ]
机构：
[1] Emory Univ, Dept Pediat, Atlanta, GA USA
[2] Emory Univ, Dept Ophthalmol, Atlanta, GA USA
[3] Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA USA
[4] Emory Univ, Dept Pediat, 1400 Tullie Rd NE, Atlanta, GA 30329 USA
来源：
PEDIATRIC BLOOD & CANCER | 2023年 / 70卷 / 12期
关键词：
Gliomas; low-grade; neuro-oncology; outcomes research; PEDIATRIC-PATIENTS; CHILDREN; VISION;
D O I：
10.1002/pbc.30668
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In optic pathway glioma (OPG), bevacizumab-based therapy (BBT) has promising effects on radiographic tumor burden, but the impact on vision is less clear. This single-institution study characterized visual acuity (VA) and visual field (VF) outcomes in 17 pediatric OPG patients treated with BBT. VA was stable or improved in 14 patients. Nine patients had evaluable VF data, six of whom experienced stability or improvement. Among six patients with vision deterioration as a treatment indication, stable or improved was observed for both VA and VF in five patients. In summary, BBT was associated with favorable visual outcomes in this cohort of patients with OPG.
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date
    Chinot, Olivier L.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1413 - 1427
  • [42] Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review
    Fumiyuki Yamasaki
    Motoki Takano
    Ushio Yonezawa
    Akira Taguchi
    Manish Kolakshyapati
    Hideaki Okumichi
    Yoshiaki Kiuchi
    Kaoru Kurisu
    Child's Nervous System, 2020, 36 : 635 - 639
  • [43] Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review
    Yamasaki, Fumiyuki
    Takano, Motoki
    Yonezawa, Ushio
    Taguchi, Akira
    Kolakshyapati, Manish
    Okumichi, Hideaki
    Kiuchi, Yoshiaki
    Kurisu, Kaoru
    CHILDS NERVOUS SYSTEM, 2020, 36 (03) : 635 - 639
  • [44] Impact of systemic anticancer therapy in pediatric optic pathway glioma on visual function: A systematic review
    Bennebroek, Carlien A. M.
    Wijninga, Laura E.
    Limpens, Jaqueline
    Schouten-van Meeteren, Antoinette Y. N.
    Saeed, Peerooz
    PLOS ONE, 2021, 16 (10):
  • [45] Bevacizumab: Good for the Eyes and the MRI's! Assessment of Visual and Radiological Outcomes of Bevacizumab Therapy in Paediatric Low-Grade Glioma
    Green, K.
    Panagopoulou, P.
    D'Arco, F.
    O'Hare, P.
    Bowman, R.
    Walters, B.
    Jain, N.
    Oostveen, M.
    Opocher, E.
    Hargrave, D.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S232 - S233
  • [46] Visual Function and Optic Pathway Glioma: A Critical Response reply
    Parsa, Cameron F.
    JAMA OPHTHALMOLOGY, 2013, 131 (01) : 121 - 124
  • [47] Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre Study
    Bennebroek, Carlien A. M.
    van Zwol, Judith
    Porro, Giorgio L.
    Oostenbrink, Rianne
    Dittrich, Anne T. M.
    Groot, Annabel L. W.
    Pott, Jan W.
    Janssen, Etienne J. M.
    Bauer, Noel J.
    van Genderen, Maria M.
    Saeed, Peerooz
    Lequin, Maarten H.
    de Graaf, Pim
    Schouten-van Meeteren, Antoinette Y. N.
    CANCERS, 2022, 14 (24)
  • [48] Visual outcome including visual field defects after treatment of paediatric optic pathway glioma: A nationwide cohort study
    Bennebroek, C. A. M.
    van Zwol, J.
    Montauban van Swijndregt, M. C.
    Loudon, S. E.
    Groot, A. L. W.
    Bauer, N. J. C.
    Pott, J. W.
    Notting, I. C.
    van Sorge, A. J.
    van Genderen, M. M.
    de Graaf, P.
    Schouten-van Meeteren, A. Y. N.
    Saeed, P.
    Porro, G. L.
    ACTA OPHTHALMOLOGICA, 2025,
  • [49] Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases
    Berghoff, Anna Sophie
    Breckwoldt, Michael Oliver
    Riedemann, Lars
    Karimian-Jazi, Kianush
    Loew, Sarah
    Schlieter, Franziska
    Furtner, Julia
    Cinci, Marc
    Thomas, Michael
    Strowitzki, Moritz J.
    Marme, Frederik
    Michel, Laura L.
    Schmidt, Thomas
    Jaeger, Dirk
    Bendszus, Martin
    Preusser, Matthias
    Wick, Wolfgang
    Winkler, Frank
    NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
  • [50] Necrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapy
    Cottu, P. H.
    Fourchotte, V.
    Vincent-Salomon, A.
    Kriegel, I.
    Fromantin, I.
    JOURNAL OF WOUND CARE, 2011, 20 (09) : 403 - +
12345